首页>
外国专利>
USE OF AFLIBERCEPT AND DOCETAXEL FOR THE TREATMENT OF NASOPHARYNGEAL CARCINOMA
USE OF AFLIBERCEPT AND DOCETAXEL FOR THE TREATMENT OF NASOPHARYNGEAL CARCINOMA
展开▼
机译:针灸和DOCETAXEL治疗鼻咽癌
展开▼
页面导航
摘要
著录项
相似文献
摘要
The present invention concerns a polypeptide comprising SEQ ID NO: 1 or a biosimilar thereof, and a combined preparation or a composition comprising a polypeptide comprising SEQ ID NO: 1 or a biosimilar thereof and docetaxel, for use for treating patients with nasopharyngeal carcinoma. The invention also pertains to an article of manufacture comprising a packaging material, a polypeptide of SEQ ID NO: 1, or a biosimilar thereof, and a label or package insert contained within said packaging material indicating that the polypeptide or biosimilar thereof is indicated for patients with nasopharyngeal carcinoma. The invention further relates to a safe therapeutic dose of a polypeptide comprising SEQ ID NO: 1 or a biosimilar thereof, in combination with docetaxel, for use for treating patients with nasopharyngeal carcinoma. In one embodiment, the polypeptide is aflibercept.
展开▼
机译:本发明涉及用于治疗鼻咽癌患者的包含SEQ ID NO:1或其生物类似物的多肽,以及包含SEQ ID NO:1或其生物类似物的多肽和多西他赛的组合制剂或组合物。本发明还涉及一种制品,该制品包括包装材料,SEQ ID NO:1的多肽或其生物类似物,以及包含在所述包装材料中的标签或包装插页,指示为患者指示了该多肽或其生物类似物与鼻咽癌。本发明还涉及与多西紫杉醇组合的安全治疗剂量的包含SEQ ID NO:1或其生物类似物的多肽,用于治疗鼻咽癌患者。在一实施方案中,该多肽是阿非西普。
展开▼